July 10, 2017 / 5:42 AM / a month ago

BRIEF-Bioinvent and Thrombogenics amend monoclonal antibody development agreement

July 10 (Reuters) - THROMBOGENICS NV:

* BIOINVENT AND THROMBOGENICS AMENDING LONG-STANDING MONOCLONAL ANTIBODY DEVELOPMENT AGREEMENT

* AGREED TO AMEND THEIR LONG-STANDING AGREEMENT, WHICH COVERS CO-DEVELOPMENT OF NOVEL ANTI-PLGF MONOCLONAL ANTIBODY PRODUCTS TB-403 AND THR-317.

* ‍UNDER CURRENT AGREEMENT, SPLIT ECONOMIC VALUE COMPOUNDS IS 60:40 (THROMBOGENICS: BIOINVENT), WITH 50:50 COST SPLIT FOR DEVELOPMENT COSTS​

* THR-317 - THROMBOGENICS GAINS FULL AND EXCLUSIVE OWNERSHIP OF THR-317 FOR DEVELOPMENT AND COMMERCIALIZATION IN ALL NON-ONCOLOGY INDICATIONS.

* THROMBOGENICS - UNDER NEW ARRANGEMENT BIOINVENT ASSUMES PROJECT LEAD FOR DEVELOPMENTS OF TB-403 IN ALL ONCOLOGY INDICATIONS, AND INCREASES SHARE ECONOMIC VALUE TO 50 PERCENT ​

* BIOINVENT ASSUMES PROJECT LEAD FOR DEVELOPMENTS OF TB-403 IN ALL ONCOLOGY INDICATIONS; INCREASES ITS SHARE OF ECONOMIC VALUE FROM 40 TO 50 PERCENT SOURCE TEXT FOR EIKON: FURTHER COMPANY COVERAGE: (Gdynia Newsroom:)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below